Back
ESC2025 Premium Access

A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF): preliminary results at 3 months follow up

Session: Novel insights into heart failure therapy
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Doctor S. Prosperi (Rome, IT)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Silvia Prosperi

Sapienza University of Rome, Rome (Italy)
1 presentation
0 follower

7 more presentations in this session

Long term efficacy and safety of sacubitril/valsartan in chronic heart failure patients with reduced ejection fraction: a prospective real-world study.

Speaker: Doctor E. Brangi (Brescia, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Real-world eligibility and tolerance of vericiguat in HFrEF patients: insights from a multicentric registry

Speaker: Doctor M. Mazzini (Brescia, IT)

Access
Abstract
Slides
Like
Thumbnail

Hemodynamic effect of angiotensin-neprilysin inhibition in diastolic dysfunction after acute myocardial infarction

Speaker: Mr P. Hartmund Frederiksen (Odense, DK)

Access
Abstract
Slides
Video
Like
Thumbnail

The rhythm control strategy in patients with atrial fibrillation and heart failure with preserved or reduced ejection fraction: the single centre experience

Speaker: Doctor M. Pandrc (Belgrade, RS)

Access
Abstract
Slides
Video
Like
Thumbnail

Clinical outcomes for patients with severe HFrEF diagnosed and treated in a community setting with the 'four pillars' of pharmacotherapy

Speaker: Doctor R. Bain (Grimsby, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Novel insights into heart failure therapy

Speakers: Doctor S. Prosperi, Doctor E. Brangi, Doctor M. Mazzini, Mr P. Hartmund Frederiksen, Doctor M. Pandrc...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources